TABLE 2.
Clinicopathological Characteristics of Metastatic Melanoma in Relation to BRAF Mutation Status and Use of BRAFi
| Variable | Entire cohort | Group A | Group B | Group C |
|---|---|---|---|---|
| No. of patients | 198 | 23 | 67 | 108 |
| Age at BM (yr) | ||||
| Median | 62 | 58 | 53 | 66 |
| Mean ± SD | 62 ± 13.8 | 58 ± 15.9 | 53 ± 13.1 | 66 ± 11.9 |
| Range | 20-86 | 20-83 | 21-81 | 25-86 |
| KPS score median (range) | 90 (40-100) | 90 (70-100) | 100 (50-100) | 90 (40-100) |
| Mean number of cerebral metastases ± SD | 3.7 ± 4.2 | 4 ± 3.6 | 4 ± 5.2 | 3.4 ± 3.7 |
| Average metastasis volume ± SD | 1.1 ± 2.6 | 1.4 ± 2.6 | 1 ± 2.6 | 1.1 ± 2.6 |
| Diagnosis interval (mo) | ||||
| Median | 34 | 32 | 42 | 31 |
| Range | 0-451 | 0-368 | 0-451 | 0-271 |
| SRS | ||||
| Mean isodose line (range; %) | 63.2 (16-97) | 58.6 (16-97) | 63.8 (32-97) | 64.1 (40-97) |
| Mean margin dose (Gy) | 19.1 ± 2.3 | 19.7 ± 1.7 | 19.2 ± 2.0 | 18.9 ± 2.6 |
| Mean repeat SRS local (range) | 0.47 (0-3) | 0.35 (0-2) | 0.57 (0-2) | 0.43 (0-3) |
| Mean repeat SRS remote (range) | 0.47 (0-3) | 0.35 (0-2) | 0.55 (0-3) | 0.45 (0-3) |
| WBRT status (%) | ||||
| None | 149 (75%) | 20 (87%) | 45 (67%) | 85 (79%) |
| Prior to SRS | 29 (15%) | 3 (13%) | 14 (21%) | 12 (11%) |
| Salvage after SRS | 19 (10%) | 0 | 8 (12%) | 11 (10%) |
| Craniotomy and resection prior to SRS (%) | 44 (22%) | 7 (30%) | 12 (18%) | 25 (23%) |